Table A1.

WECARE Study Final Enrollment, Data Collection, and BRCA1/BRCA2 Genotyping by Center and Case-Control Status

Variable	Denmark		Iowa		FHCRC		UCI		USC		Total
	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
Eligible and approached	267	541	133	292	127	246	164	316	307	717	998	2,112
Nonparticipants	88	183	20	64	28	53	46	87	108	326	290	713
Physician refusal	0	0	0	10	5	13	0	0	0	0	5	23
Subject interview refusal	88	180	20	46	21	40	39	75	97	307	265	648
Subject blood draw refusal	0	3	0	8	2	0	7	12	11	19	20	42
Participated and analyzed*	179	358	113	228	99	193	118	229	199	391	708	1,399
Medical record abstraction	179	358	113	228	97	192	118	229	199	391	706	1,398
BRCA genotyping	176	357	113	228	99	193	118	229	199	391	705	1,398

Abbreviations: FHCRC, Fred Hutchinson Cancer Research Center; UCI, University of California at Irvine; USC, University of Southern California at Los Angeles.

^*Enrollment efforts were conducted from January 2000 to July 2004 at five data collection sites (four in the United States and one in Denmark). A total of 998 women with contralateral breast cancer were eligible and were approached for inclusion in the study during the period January 2000-July 2004; 708 of these women (71%) agreed to participate. Of the 2,112 women who were selected as potential controls and met the eligibility criteria, 1,399 (66%) agreed to participate. A woman was considered to have participated successfully if she completed both the interview and the blood collection.